UT Southwestern Medical Center researchers discovered a method cells use to turn genes on and off that involves portions of proteins whose function has long been a mystery. The findings, reported in Cell, could lead to new ways of controlling gene regulation and may one day lead to new treatments for a broad array of diseases.
Utilizing artificial intelligence along with traditional pathology offers promise for swiftly developing treatment plans for patients with non-small cell lung cancers, a team led by UT Southwestern Medical Center researchers discovered.
FDA approved Jemperli (dostarlimab-gxly) for adult patients with mismatch repair deficient recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
Absci Corporation and St. John’s Cancer Institute entered into a partnership to uncover breakthrough cancer therapies. The partnership will leverage Absci’s Integrated Drug Creation platform, which combines generative AI models and proprietary wet-lab technologies, and SJCI’s cancer biospecimen repository and molecular database to quickly identify new therapeutic candidates with the potential for higher probability of clinical success.
Ten miles south of my job at the Chao Family Comprehensive Cancer Center, an Asian American elder opened fire and killed one person at the Taiwanese Presbyterian Church in Laguna Woods, CA.
Cancer Treatment Centers of America will “fully transition” to City of Hope’s brand, giving the southern California-based cancer care health system a national footprint.
The National Cancer Institute defines precision medicine in cancer as a strategy that “uses specific information about a person’s tumor to help make a diagnosis, plan treatment, find out how well treatment is working, or make a prognosis.”1
The Mark Foundation for Cancer Research has given two new Drug Discovery Awards.
Laleh Amiri-Kordestani was named acting associate director for cardio-oncology in the FDA Oncology Center of Excellence. She will also continue her role as the division director for the Division of Oncology 1.
Sven Davisson was named associate director of administration at Louisiana Cancer Research Center.
